These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27616450)

  • 1. Sympathetic Nerve Activity Efferent Drive and Beta-Blocker Treatment　- Effect of Interaction in Systolic Heart Failure.
    Joho S; Akabane T; Ushijima R; Hirai T; Kinugawa K
    Circ J; 2016 Sep; 80(10):2149-54. PubMed ID: 27616450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between prognostic impact of hyperuricemia and sympathetic overactivation in patients with heart failure.
    Joho S; Ushijima R; Nakagaito M; Kinugawa K
    J Cardiol; 2019 Mar; 73(3):233-239. PubMed ID: 30420104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sympathetic overactivation predicts body weight loss in patients with heart failure.
    Joho S; Ushijima R; Nakagaito M; Kinugawa K
    Auton Neurosci; 2020 Jan; 223():102625. PubMed ID: 31896025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol.
    Fraga R; Franco FG; Roveda F; de Matos LN; Braga AM; Rondon MU; Rotta DR; Brum PC; Barretto AC; Middlekauff HR; Negrão CE
    Eur J Heart Fail; 2007; 9(6-7):630-6. PubMed ID: 17475552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure.
    Usui K; Bradley TD; Spaak J; Ryan CM; Kubo T; Kaneko Y; Floras JS
    J Am Coll Cardiol; 2005 Jun; 45(12):2008-11. PubMed ID: 15963401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased muscle sympathetic nerve activity predicts mortality in heart failure patients.
    Barretto AC; Santos AC; Munhoz R; Rondon MU; Franco FG; Trombetta IC; Roveda F; de Matos LN; Braga AM; Middlekauff HR; Negrão CE
    Int J Cardiol; 2009 Jul; 135(3):302-7. PubMed ID: 18582965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of low-frequency variability of sympathetic nerve activity in severe heart failure.
    van de Borne P; Montano N; Pagani M; Oren R; Somers VK
    Circulation; 1997 Mar; 95(6):1449-54. PubMed ID: 9118512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
    Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
    Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance.
    Cohen-Solal A; Jacobson AF; Piña IL
    ESC Heart Fail; 2017 Nov; 4(4):499-506. PubMed ID: 29154422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea.
    Spaak J; Egri ZJ; Kubo T; Yu E; Ando S; Kaneko Y; Usui K; Bradley TD; Floras JS
    Hypertension; 2005 Dec; 46(6):1327-32. PubMed ID: 16286569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?
    Porapakkham P; Porapakkham P; Krum H
    Cardiovasc Ther; 2010 Apr; 28(2):93-100. PubMed ID: 20398098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
    Wikstrand J; Wedel H; Castagno D; McMurray JJ
    J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers.
    Pascual-Figal DA; Redondo B; Caro C; Manzano S; Garrido IP; Ruipérez JA; Valdés M
    Am J Cardiol; 2008 Dec; 102(12):1711-7. PubMed ID: 19064029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microneurography and venous occlusion plethysmography in heart failure: correlation with prognosis.
    Munhoz RT; Negrão CE; Barretto AC; Ochiai ME; Cardoso JN; Morgado PC; Del Carlo CH; Ramires JA
    Arq Bras Cardiol; 2009 Jan; 92(1):46-53. PubMed ID: 19219264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restrictive Lung Function Is Related to Sympathetic Hyperactivity in Patients With Heart Failure.
    Joho S; Ushijima R; Akabane T; Hirai T; Inoue H
    J Card Fail; 2017 Feb; 23(2):96-103. PubMed ID: 27288844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal insufficiency coexisting with heart failure is related to elevated sympathetic nerve activity.
    Oda Y; Joho S; Harada D; Hirai T; Asanoi H; Inoue H
    Auton Neurosci; 2010 Jun; 155(1-2):104-8. PubMed ID: 20123156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
    Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
    Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
    Mentz RJ; Schmidt PH; Kwasny MJ; Ambrosy AP; O'Connor CM; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Gheorghiade M
    J Card Fail; 2012 Jul; 18(7):515-23. PubMed ID: 22748484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.